Q-omics provides the consensus-scored BCAS3 profile across patient tissues and cancer cell-line models. BCAS3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BCAS3 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, BCAS3 protein abundance shows 21,915 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where BCAS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCAS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCAS3 survival associations across molecular data types. BCAS3 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCAS3 RNA expression–survival associations across cancer types. High BCAS3 expression shows favorable associations in KIRC, SCLC, PAAD, READ, CESC and PRAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BCAS3 RNA expression.
This table summarizes BCAS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BCAS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCAS3 shows lower tumor expression in KICH, THCA and UCEC and higher tumor expression in LIHC, HNSC and CHOL. The KICH box plot shows higher BCAS3 RNA expression in normal versus tumor tissue (log2 FC = −1.246, t-test p < 0.001).
This table shows molecular features associated with BCAS3 in patient tissues and cancer cell lines. In patient samples, BCAS3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, BCAS3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
